NCT03157128 · MORE INFO

Limitations, agreements, and source contact

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: GT60
restrictive Agreement: true

point Of Contact

email: ClinicalTrials.gov@lilly.com
organization: Eli Lilly and Company
phone: 08005455979
title: Chief Medical Officer

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: GT60
restrictive Agreement: true

point Of Contact

email: ClinicalTrials.gov@lilly.com
organization: Eli Lilly and Company
phone: 08005455979
title: Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice